Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen: Results of a double-blind randomised phase III trial

European Journal of Cancer

Volumn 36, Issue SUPPL. 4, 2000, Pages 86-87

  Kaufmann, M ^a   Bajetta, E ^b   Dirix, L Y ^c   Fein, L E ^d   Jones, S E ^e   Cervek, J ^f   Fowst, C ^g   Polli, A ^g   Di Salle, E ^g   Massimini, G ^g   Piscitelli, G ^g  

^a GOETHE UNIVERSITY   (Germany)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c SINT AUGUSTINUS HOSPITAL   (Belgium)

^d Ctro Oncol de Rosario Santa Fe   (Argentina)

^e University of South Carolina   (United States)

^f INSTITUTE OF ONCOLOGY   (Slovenia)

^g PFIZER INC   (United States)

Author keywords

Antineoplastic agents; Aromatase; Breast neoplasms; Enzyme inhibitor; Hormonal; Megoestrol acetate

Indexed keywords

AROMATASE INHIBITOR; EXEMESTANE; MEGESTROL ACETATE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0033736549     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(00)00240-9     Document Type: Article

References (2)

1. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
2. Anastrazole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combine analysis of data from two mature phase III trials